Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (December 2015)
25 slides from Prescient Therapeutics's investor presentation, Dec 1, 2015
Slide 1: The best value healthcare stock on ASX?
For personal use only The best value healthcare stock on ASX? » Phase 1b/2 Breast cancer » Phase 1b Ovarian cancer » …and soon Phase 1b AML December 2015
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor For personal use only Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical fa
Slide 3: Investment Highlights
Investment Highlights For personal use only One of Deepest Clinical 3 clinical trials: 2 underway and 1 on track to initiate 1H 2016, all under Pipelines on ASX IND Two Clinical Stage 2 drug candidates targeting key cancer pathways Oncology Drugs » Akt (PTX-200) and Ras (PTX-100) Distinguished Scien
Slide 4: Deep, Clinical Stage Product Pipeline
Deep, Clinical Stage Product Pipeline For personal use only PTX has one of the deepest and most mature product pipelines on ASX Discovery Screening Preclinical Phase I Phase Ib Phase II Phase III PTX-200 Breast Cancer Finishing PTX-200 Ovarian Cancer Underway PTX-200 AML Early 2016 PTX-100 Breast Ca
Slide 5: Corporate Snapshot
Corporate Snapshot For personal use only Key Metrics Shareholder Base ASX Ticker PTX Total Issued Capital 93.7 M shares Board & 7.6 M Management: 12% Options (various) Share Price1 A$0.07 Market Capitalisation1 A$6.5 M Cash Position2 A$2.4 M Top 20 Own 33% 6 month turnover1 22.4 M shares Retail/HNW:
Slide 6: PTX's valuation obviously doesn't weigh up!
PTX’s valuation obviously doesn’t weigh up! For personal use only >$20 M Prestigious already Two novel invested Technology technology founders platforms targeting Akt and Ras/Rho Two INDs inhibition Mechanism open in breast & of Action well ovarian cancer understood Phase 1b ovarian trial recruiting
Slide 7: How Our Drugs Work: "Molecular Switches"
How Our Drugs Work: “Molecular Switches” For personal use only Akt & Ras are growth factors PTX’s drugs block the Akt & found in cancer cells – Ras growth signals, when they are turned on, switching the growth signals they send a signal to the off and causing the cancer cancer cell to grow cell to d
Slide 8: What is Chemoresistance?
What is Chemoresistance? For personal use only • Despite the many advances in cancer treatment over many decades, 90% of advanced cancer patients become resistant to chemotherapy • Resistance comes about when some of the cells that are not killed by the chemotherapy mutate (change) and become resist
Slide 9: World Class Centres & Collaborations
World Class Centres & Collaborations For personal use only New York Florida Previous clinical trials conducted at: 9
Slide 10: Introducing the Moffitt Cancer Center
Introducing the Moffitt Cancer Center • H. Lee Moffitt Cancer Center & For personal use only Research Institute, established in 1986 in Tampa, Florida • 3rd largest cancer centre in the US • On one side of the campus is a world- leading “comprehensive cancer clinic” » offering patients medical oncol
Slide 11: Drugs Don't Develop Themselves!
Drugs Don’t Develop Themselves! For personal use only Said Sebti, PhD Terry Chew, M.D. Chief Scientific Officer Chief Medical Officer • Professor and Chair, Department of Drug Discovery - • Hematologist/oncologist with 20 years experience in biotech & Moffitt Cancer Center pharma • Co-Program Leader
Slide 12: Clinical Advocates Driving Our Programs
Clinical Advocates Driving Our Programs For personal use only Acute Myeloid Breast Cancer Ovarian Cancer Leukemia Joseph Sparano, M.D. Heather Han, M.D. Robert Wenham, M.D. Jeff Lancet, M.D. • Prof. of Medicine & • Assistant Prof. of • Section Head, • Prof. of Oncologic Obstetrics, Gynecology, Medic
Slide 13: Board of Directors
Board of Directors For personal use only • Experienced, complementary, and collaborative Steve Engle • Former Chairman and CEO of US-listed XOMA (NASDAQ:XOMA) and La Jolla Non-Executive Pharmaceuticals (NASDAQ: LJPC) Chairman • Currently CEO of Averigon Consulting, an advisory firm to life science i
Slide 14: World Class Scientific Advisory Board
World Class Scientific Advisory Board For personal use only • Genuine international authorities, with particularly strong expertise in leukaemia • Professor, Department of Leukemia, Division of Cancer Medicine, The University of Farhad Ravandi, Texas MD Anderson Cancer Center, Houston, Texas M.D. •
Slide 15: Breast Cancer Market Overview
Breast Cancer Market Overview • Breast cancer market currently US$10 B; due to double by 2023 For personal use only • Most breast cancer drug sales are for HER2+ cancers, but this only represents ̴20% of all breast cancers • By contrast, PTX is targeting “HER2 negative” (HER2-) breast cancer • HER2-
Slide 16: Phase 1b Breast Cancer Trial Almost Completed
Phase 1b Breast Cancer Trial Almost Completed For personal use only • PTX-200 plus Taxol in patients with metastatic and locally advanced breast cancer » Phase 1b trial currently underway » Recruiting at Albert Einstein College of Medicine Montefiore Medical Center Joseph Sparano, M.D. » Funded by N
Slide 17: Phase 2 Breast Cancer Trial to Commence Early 2016
Phase 2 Breast Cancer Trial to Commence Early 2016 For personal use only • Dr Heather Han at Moffitt to join Phase 2 recruitment • Phase 2 to commence 1H 2016 • Patients with metastatic and locally advanced breast cancer Joseph Sparano, M.D. • PTX-200 in combination with paclitaxel, followed by doxo
Slide 18: Ovarian Cancer Market Overview
Ovarian Cancer Market Overview For personal use only • One of the most common cancers in women -increasing with an ageing population • Due to reach US$1.7 B by 2019 » Market size currently constrained by old generic drugs that just aren’t good enough • Standard of care is “platinum based” drugs (oft
Slide 19: Phase 1b Ovarian Cancer Trial Already Underway
Phase 1b Ovarian Cancer Trial Already Underway For personal use only • PTX-200 plus Carboplatin in platinum resistant ovarian cancer • Significant need for new products to treat platinum-resistant ovarian cancer • Phase 1b already underway Robert Wenham, M.D. Principal Investigator • IND transferred
Slide 20: Acute Myeloid Leukaemia Market Overview
Acute Myeloid Leukaemia Market Overview • AML is a type of cancer that affects the blood and bone marrow. For personal use only » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly & 5-year survival is a dismal 25% • More comm
Slide 21: PTX-200: Completed Phase in AML
PTX-200: Completed Phase 1 in AML For personal use only Patients 32 Trial Centers MD Anderson & Moffitt Patient Advanced hematologic malignancies (mainly AML) Inclusion Administration 1 hour IV infusion on days 1, 8, and 15. Methods Cycles repeated every 21 days. Study To establish dosing regime and
Slide 22: Planned Phase 1b Trial: Acute Myeloid Leukemia
Planned Phase 1b Trial: Acute Myeloid Leukemia For personal use only . • PTX-200 plus cytarabine in refractory or relapsed acute leukemia • Phase 1 results very encouraging • Phase 1b/2 now planned • Protocol complete Jeffrey E Lancet, M.D. Principal Investigator • Moffitt Cancer Centre ready to rec
Slide 23: What To Watch Out For
What To Watch Out For For personal use only 2014 2015 1H 2016 2H 2016 Transfer Breast Cancer IND Breast Complete Phase 1b cancer Initiate Phase 2 Initiate Phase 1b Ovarian Transfer Ovarian Cancer IND cancer Dose escalation and interim analysis Complete Phase 1b IND allowed by US FDA Acute Myeloi
Slide 24: Investment Summary
Investment Summary For personal use only • Two clinical stage cancer drugs from top US institutions (Yale and Moffitt) • Two clinical trials currently underway: » Breast cancer » Ovarian cancer • 3rd trial starting early 2016 in Acute Myeloid Leukaemia » A massive unmet market » Intense market inter
Slide 25: Contact
For personal use only Contact Paul Hopper Executive Director Prescient Therapeutics Limited M: +61 406 671 515 E: receptogen@earthlink.net prescienttherapeutics.com
Prescient Therapeutics — Investor Presentation (December 2015) on 6ix